Using bright light therapy to help with alcohol withdrawal
Bright Light Therapy During Residential Alcohol Withdrawal : a Double Blind Randomized Placebo Controlled Study
NA · Centre Hospitalier St Anne · NCT06878287
This study is testing if bright light therapy can help people aged 18 to 65 going through alcohol withdrawal feel better compared to a fake light treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Centre Hospitalier St Anne (other) |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT06878287 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of bright light therapy compared to a placebo in patients undergoing alcohol withdrawal. Eligible participants, aged 18 to 65 with a diagnosis of Alcohol Use Disorder, will be hospitalized for 14 days and randomly assigned to receive either active light therapy or placebo light therapy. The therapy will be administered daily for 30 minutes each morning during the withdrawal period. The study aims to assess whether light therapy can improve withdrawal outcomes without altering standard care practices.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with a diagnosis of Alcohol Use Disorder who are undergoing treatment for alcohol withdrawal.
Not a fit: Patients with significant ophthalmic conditions or severe psychiatric comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the management of alcohol withdrawal and improve patient outcomes.
How similar studies have performed: While the use of light therapy in this context is relatively novel, similar studies in other areas have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be aged from 18 to 65 years old and have a diagnosis of Alcohol Use Disorder * Patients must be intreated for alcohol withdrawal, for at least two weeks * Patients must report heavy drinking episodes in the past month * Patients must be able to understand medical information and consent to the treatment * Patients must be considering a goal of abstinence from alcohol Exclusion Criteria: * Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitis pigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.) * Subjects who have already received light therapy in the last 6 months * Lactating of pregnant women * Psychiatric comorbidity requiring an intreatment, or risk of manic episode (subjects with depressive or anxious symptoms compatible with an out-treatment can be included) * Substance Use Disorder other than alcohol and/or tobacco * Severe cognitive impairment (MOCA \< 10) * Patients being under legal protection measure
Where this trial is running
Paris, Île-de-France Region
- Adult Emergency Department - Bichât Hospital — Paris, Île-de-France Region, France (RECRUITING)
Study contacts
- Principal investigator: Pierre Alexis GEOFFROY, PhD — University Hospital Group for Psychiatry and Neurosciences
- Study coordinator: Pierre Alexis GEOFFROY, PhD
- Email: pierrealexis.geoffroy@aphp.fr
- Phone: +33140256048
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alcohol Use Disorder, Alcohol Withdrawal